The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Gresham House and Gresham House Strategic make up

Thu, 10th Jun 2021 16:31

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Gresham House Strategic PLC - Largest shareholder Gresham House PLC withdraws requisition notice for general meeting issued last month, following discussions. Gresham House, a 23% shareholder, had wanted the immediate removal of David Potter as chair, rather than at GHS's annual general meeting, then scheduled for September. The AGM now will brought forward and held no later than July 26, at which Potter will retire. GHS is seeking a new chair, but if one is not found by the time of the AGM, then Non-Executive Director Helen Sinclair will act as interim chair. Senior Independent Director Ken Lever will lead a strategy review "with a view to determining the best means of maximising value for all shareholders". Also appoints Graham Bird as a non-independent non-executive director, effective immediately. Bird is chief financial officer of escape room chain Escape Hunt PLC and had previously been fund manager of GHS as an employee of Gresham House Asset Management Ltd.

----------

Kosmos Energy Ltd - oil and gas exploration and production along Atlantic Margins, including offshore Ghana and Equatorial Guinea and in the US Gulf of Mexico - Roy Franklin joins board from Wednesday. Franklin is chair of FTSE 250 energy services company John Wood Group PLC. He started his career at BP PLC and was chair of Premier Oil PLC until it was acquired by Chrysaor Holdings Ltd and relisted in London as Harbour Energy PLC.

----------

UniVision Engineering Ltd - Hong Kong-based supply, design, installation and maintenance of closed circuit television and surveillance systems - Edward Li resigns as director and will leave company "by mutual agreement" on July 1. Li was promoted to executive director only in June of last year. He was senior project manager for Univision's contract with the Hong Kong metro system and became projects director. UniVision is looking for a replacement.

----------

Arecor Therapeutics PLC - Saffron Walden, England-based biopharmaceuticals - Hires Lindsey Foulkes as chief operating officer. Foulkes was a consultant at McKinsey & Co and most recently was senior director of Business Development at Nasdaq-listed Liminal Biosciences Inc. Arecor debuted on AIM last week.

----------

Love Hemp Group PLC - London-based cannabidiol products maker - Hires James Martin as COO, effective immediately, charged with managing the company's growth strategy. Notes Martin has worked for Royal Dutch Shell PLC, Vodafone Group PLC, GlaxoSmithKline PLC, and accountants PwC. Also hires Anna Legge as chief communications officer and Martin Healy as chief growth officer. Legge was director of Communications at London-listed miner SolGold PLC. Love Hemp says Healy, previously head of Advertising Sales & Partnerships at Walt Disney Co, will work on international growth and commercial relationships, allowing Chief Commercial Officer Adam Pritchard to focus on the UK.

----------

Celtic PLC - Glasgow football club - Hires Ange Postecoglou as the club's first team manager, starting immediately. Postecoglou, a former manager of the Australian national team, replaces Neil Lennon, who resigned in February after Celtic failed to secure a record 10th consecutive Scottish Premiership title.

----------

BMO Managed Portfolio Trust PLC - invests in underlying investment companies for diversification - Hires Simon Longfellow as non-executive director, starting July 14. Longfellow was head of Investment Trust Marketing at Janus Henderson Investors.

----------

AEX Gold Inc - miner in Greenland - Line Frederiksen and David Neuhauser join board as non-executive directors following vote at AGM on Wednesday. Frederiksen is chief financial officer for Greenland-based telecom services provider Tele Greenland AS. Neuhauser is founder & managing director of hedge fund Livermore Partners in Chicago, a 6.0% shareholder in AEX Gold.

----------

Amati AIM VCT PLC - venture capital trust - Confirms Fiona Wollocombe as non-executive director, starting Thursday. Says Wollocombe has "extensive knowledge and experience in the VCT industry". Wollocombe is chair designate of Kings Arms Yard VCT PLC, Amati notes. As an executive, she worked in equity capital markets at NatWest Markets, part of NatWest Group PLC, and Deutsche Bank AG.

----------

N Brown Group PLC - Manchester-based online retailer - Confirms the appointment of Dominic Platt as independent non-executive director, starting immediately. Platt is CFO of BGL Group, a distributor of insurance and household financial services, having previously been finance director and managing director of international business at electricals retailer Darty PLC.

----------

Law Debenture Corp PLC - London-based investor and provider of pension and trust services - Hires Clare Askem as non-executive director, effective immediately. Askem also is non-executive director of homewares maker Portmeirion Group PLC and of Studio Retail Group PLC. Askem was managing director of Habitat at J Sainsbury PLC and also was an executive at Home Retail Group and Dixons Carphone PLC.

----------

Treatt PLC - Bury St Edmunds, Suffolk-based ingredients for food, beverage and fragrance - Non-Executive Director Richard Illek to step down from board on December 31, having served since June 2016.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.